专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011152657A2 ACETYL-L-CARNITINE MALATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
标题翻译：乙酰胆碱 - 马来酸酐，其制备方法和包含其的药物组合物
公开(公告)号：WO2011152657A2
公开(公告)日：2011-12-08
申请号：PCT/KR2011004002
申请日：2011-06-01
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC , KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , KIM DONG YOUN , KIM JOON WOO , CHO KYOUNG-SUK , YU KEEWON , KWON HYUK JIN
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , KIM DONG YOUN , KIM JOON WOO , CHO KYOUNG-SUK , YU KEEWON , KWON HYUK JIN
IPC分类号： C07C229/22 , A61K31/197 , A61P25/28 , C07C227/16
CPC分类号： C07C229/22 , C07C59/01
摘要： The present invention relates to acetyl-L-carnitine malate, a process for preparing the same, and a pharmaceutical composition comprising the same. The acetyl-L-carnitine malate of the present invention has good stability, solubility, and non-hygroscopicity to be effectively used for preparing a pharmaceutical composition.
摘要翻译：本发明涉及苹果酸乙酰基-L-肉碱，其制备方法，以及包含其的药物组合物。本发明的乙酰基-L-肉碱苹果酸酯具有良好的稳定性，溶解性和非吸湿性，可有效地用于制备药物组合物。

2. 发明申请

WO2011152658A3 PHARMACEUTICAL COMPOSITION COMPRISING PIPERAZINE DITHIOCTATE AND GLIMEPIRIDE 审中-公开
标题翻译：药物组合物，包括哌嗪脱氢和吡咯
公开(公告)号：WO2011152658A3
公开(公告)日：2012-04-26
申请号：PCT/KR2011004004
申请日：2011-06-01
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC , KIM KYOUNG SOO , SHIN DONG SEONG , KWON HYUK JIN , PARK YOUNG JUN , CHO KYOUNG-SUK , YU KEEWON , LEE IN SUK , NOH JIN-HYOUNG , SONG HYUN-NAM , KIM DONG YOUN , KIM JOON WOO
发明人： KIM KYOUNG SOO , SHIN DONG SEONG , KWON HYUK JIN , PARK YOUNG JUN , CHO KYOUNG-SUK , YU KEEWON , LEE IN SUK , NOH JIN-HYOUNG , SONG HYUN-NAM , KIM DONG YOUN , KIM JOON WOO
IPC分类号： A61K31/495 , A61K31/40 , A61P3/10 , C07D295/027 , C07D339/02
CPC分类号： C07D339/04 , C07D207/38
摘要： The present invention relates to a pharmaceutical composition for treating or preventing type II diabetes mellitus comprising piperazine dithioctate and glimepiride, which is a new combination drug. The pharmaceutical composition of the present invention has strong synergistic effects for treating type II diabetes mellitus by improving metabolic disorders and insulin resistance of diabetic patients as well as lowering blood glucose levels, and by increasing glucose uptake in cells, compared with single treatment of piperazine dithioctate or glimepiride, or combination treatment of thioctic acid and glimepiride.
摘要翻译：本发明涉及用于治疗或预防II型糖尿病的药物组合物，其包含哌嗪二硫代酸酯和作为新组合药物的格列美脲。本发明的药物组合物通过改善糖尿病患者的代谢紊乱和胰岛素抵抗以及降低血糖水平以及通过增加细胞中的葡萄糖摄取而与治疗II型糖尿病相比具有很强的协同效应，与单次治疗哌嗪二硫代辛酸或格列美脲，或硫辛酸和格列美脲的组合治疗。

3. 发明申请

WO2012008711A3 ERLOTINIB DICHLOROACETATE AND ANTI-CANCER AGENT COMPRISING THE SAME 审中-公开
标题翻译： ERLOTINIB DICHLOROACETATE和包括其的抗癌剂
公开(公告)号：WO2012008711A3
公开(公告)日：2012-05-24
申请号：PCT/KR2011004985
申请日：2011-07-07
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC , KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , KIM DONG YOUN , KIM JOON WOO , CHO KYOUNG-SUK , YU KEEWON , KWON HYUK JIN
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , KIM DONG YOUN , KIM JOON WOO , CHO KYOUNG-SUK , YU KEEWON , KWON HYUK JIN
IPC分类号： C07D239/94 , A61K31/505 , A61P35/00
CPC分类号： A61K31/505
摘要： The present invention relates to erlotinib dichloroacetate and an anti-cancer agent comprising the same. The erlotinib dichloroacetate of the present invention can inhibit epidermal growth factor receptor as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly enhanced anti-cancer effects by synergy between erlotinib and dichloroacetic acid.
摘要翻译：本发明涉及二氯乙酸厄洛替尼及其相应的抗癌剂。本发明的二氯乙酸埃罗替尼可以抑制表皮生长因子受体，并诱导癌细胞通过细胞凋亡自身杀死，从而抑制癌细胞的生长并导致其破坏，并通过厄洛替尼与厄洛替尼之间的协同作用显着增强抗癌作用二氯乙酸。

4. 发明申请

WO2010151008A2 PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
标题翻译：哌嗪脱氢酶和包含其的药物组合物
公开(公告)号：WO2010151008A2
公开(公告)日：2010-12-29
申请号：PCT/KR2010003954
申请日：2010-06-18
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC , KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , LEE IN SUK , KIM JOON WOO
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , LEE IN SUK , KIM JOON WOO
IPC分类号： C07D339/02 , C07D339/00
CPC分类号： C07D339/02 , C07D295/027 , C07D339/04
摘要： The present invention relates to piperazine dithioctate, a novel addition salt of thioctic acid with a base and a pharmaceutical composition comprising the same. The piperazine dithioctate according to the present invention has good thermal and moisture stability and high water-solubility as well as dosage increase lower than other addition salts, thereby being effectively used for preparing a pharmaceutical composition for antioxidation or for preventing or treating diabetic polyneuropathy, etc.
摘要翻译：本发明涉及哌嗪二硫辛酸酯，硫辛酸与碱的新型加成盐和含有它们的药物组合物。根据本发明的哌嗪二硫代辛酸酯具有良好的热和水分稳定性和高水溶性以及比其它加成盐低的剂量增加，从而有效地用于制备抗氧化药物组合物或用于预防或治疗糖尿病性多发性神经病变等。

5. 发明申请

WO2011081408A3 IMATINIB DICHLOROACETATE AND ANTI-CANCER AGENT COMPRISING THE SAME 审中-公开
标题翻译： IMATINIB DICHLOROACETATE和抗癌剂包括它们
公开(公告)号：WO2011081408A3
公开(公告)日：2011-11-10
申请号：PCT/KR2010009423
申请日：2010-12-28
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC , KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , KIM JOON WOO
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , KIM JOON WOO
IPC分类号： C07D403/14 , A61K31/496 , A61P35/00 , C07D403/02
CPC分类号： A61K31/496 , C07D401/04
摘要： The present invention relates to imatinib dichloroacetate and an anti-cancer agent comprising the same. The imatinib dichloroacetate of the present invention can inhibit tyrosine kinase as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly enhanced anti-cancer effects by synergy between imatinib and dichloroacetic acid.
摘要翻译：本发明涉及伊马替尼二氯乙酸酯和包含其的抗癌剂。本发明的伊马替尼二氯乙酸盐可抑制酪氨酸激酶以及诱导癌细胞通过细胞凋亡自身杀死，从而抑制癌细胞的生长并导致其破坏，并通过伊马替尼和二氯乙酸之间的协同作用显示出显着增强的抗癌作用。

6. 发明申请

WO2010151008A3 PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
标题翻译：哌嗪脱氢酶和包含其的药物组合物
公开(公告)号：WO2010151008A3
公开(公告)日：2011-05-19
申请号：PCT/KR2010003954
申请日：2010-06-18
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC , KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , LEE IN SUK , KIM JOON WOO
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , LEE IN SUK , KIM JOON WOO
IPC分类号： C07D339/02 , C07D339/00
CPC分类号： C07D339/02 , C07D295/027 , C07D339/04
摘要： The present invention relates to piperazine dithioctate, a novel addition salt of thioctic acid with a base and a pharmaceutical composition comprising the same. The piperazine dithioctate according to the present invention has good thermal and moisture stability and high water-solubility as well as dosage increase lower than other addition salts, thereby being effectively used for preparing a pharmaceutical composition for antioxidation or for preventing or treating diabetic polyneuropathy, etc.
摘要翻译：本发明涉及哌嗪二硫辛酸酯，硫辛酸与碱的新型加成盐和含有它们的药物组合物。根据本发明的哌嗪二硫代辛酸酯具有良好的热和水分稳定性和高水溶性以及比其它加成盐低的剂量增加，从而有效地用于制备抗氧化药物组合物或用于预防或治疗糖尿病性多发性神经病变等。

7. 发明授权

KR100971486B1 Adefovir dipivoxil malonate and pharmaceutical composition including the same 无效
标题翻译： ADEFOVIR DIPIVOXIL MALONATE和药物组合物，包括它们
公开(公告)号：KR100971486B1
公开(公告)日：2010-07-21
申请号：KR20090051748
申请日：2009-06-11
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN NAM , LEE IN SUK , KIM JOON WOO
IPC分类号： C07D487/04 , C07D487/02
摘要： PURPOSE: An adefovir dipivoxil malonate is provided to ensure stability, non-absorption property, and solubility and to use in pharmaceutical composition for treating HIV and hepatitis type B infection. CONSTITUTION: An adefovir dipivoxil malonate is crystalline and is denoted by chemical formula I. The adefovir dipivoxil malonate has diffraction angle(2θ) having 10% or more of I/I0(I: peak intensity in the diffraction angle, I0: maximum peak intensity) is 8.1±0.2, 12.1±0.2, 16.1±0.2, 17.1±0.2, 19.1±0.2, 19.5±0.2, 20.9±0.2, 22.6±0.2, 24.6±0.2, 26.6±0.2, and 32.9±0.2. A pharmaceutical composition for treating HIV or hepatitis type B infection contains the adefovir dipivoxil malonate and pharmaceutically acceptable carrier.
摘要翻译：目的：提供阿德福韦酯丙二酸酯以确保稳定性，非吸收性和溶解性，并用于药物组合物用于治疗艾滋病毒和乙型肝炎感染。组成：阿德福韦酯丙二酸酯是结晶的，由化学式I表示。阿德福韦酯丙二酸酯的衍射角（2＆thgr）具有10％以上的I / I0（I：衍射角的峰强度，I0：最大峰强度）分别为8.1±0.2,12.1±0.2,16.1±0.2,17.1±0.2,19.1±0.2,19.5±0.2,20.9±0.2,22.6±0.2,24.6±0.2,26.6±0.2和32.9±0.2。用于治疗HIV或乙型肝炎感染的药物组合物含有阿德福韦酯丙二酸酯和药学上可接受的载体。

8. 发明公开

EP2445895A4 PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 有权
标题翻译：哌嗪硫酸盐及其药物组合物的研究
公开(公告)号：EP2445895A4
公开(公告)日：2012-11-28
申请号：EP10792290
申请日：2010-06-18
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , LEE IN SUK , KIM JOON WOO
IPC分类号： C07D339/02 , A61K31/385 , C07D295/027 , C07D339/00 , C07D339/04
CPC分类号： C07D339/02 , C07D295/027 , C07D339/04

9. 发明公开

EP2519518A4 IMATINIB DICHLOROACETATE AND ANTI-CANCER AGENT COMPRISING THE SAME 有权
标题翻译：二氯伊马替尼，为了抗癌剂
公开(公告)号：EP2519518A4
公开(公告)日：2013-05-22
申请号：EP10841240
申请日：2010-12-28
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , KIM JOON WOO
IPC分类号： C07D403/14 , A61K31/496 , A61P35/00 , C07D403/02
CPC分类号： A61K31/496 , C07D401/04

10. 发明专利

CA2763715A1 PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 未知
公开(公告)号：CA2763715A1
公开(公告)日：2010-12-29
申请号：CA2763715
申请日：2010-06-18
申请人： CELLTRION CHEMICAL RES INST , CELLTRION PHARM INC
发明人： KIM KYOUNG SOO , PARK YOUNG JUN , SONG HYUN-NAM , LEE IN SUK , KIM JOON WOO
IPC分类号： C07D339/02 , C07D339/00
摘要： The present invention relates to piperazine dithioctate, a novel addition salt of thioctic acid with a base and a pharmaceutical composition comprising the same. The piperazine dithioctate according to the present invention has good thermal and moisture stability and high water-solubility as well as dosage increase lower than other addition salts, thereby being effectively used for preparing a pharmaceutical composition for antioxidation or for preventing or treating diabetic polyneuropathy, etc.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式